These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
506 related items for PubMed ID: 11807679
1. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Clin Infect Dis; 2002 Mar 01; 34(5):563-71. PubMed ID: 11807679 [Abstract] [Full Text] [Related]
6. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study. Slobbe L, Polinder S, Doorduijn JK, Lugtenburg PJ, el Barzouhi A, Steyerberg EW, Rijnders BJ. Clin Infect Dis; 2008 Dec 15; 47(12):1507-12. PubMed ID: 18990068 [Abstract] [Full Text] [Related]
7. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed. Prescrire Int; 2004 Feb 15; 13(69):13-6. PubMed ID: 15055210 [Abstract] [Full Text] [Related]
8. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). Vehreschild JJ, Böhme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, Drzisga I, Cornely OA. J Infect; 2007 Nov 15; 55(5):445-9. PubMed ID: 17822770 [Abstract] [Full Text] [Related]
9. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Clin Infect Dis; 2009 Feb 01; 48(3):265-73. PubMed ID: 19115967 [Abstract] [Full Text] [Related]
10. The efficacy and tolerability of voriconazole in the treatment of chronic cavitary pulmonary aspergillosis. Jain LR, Denning DW. J Infect; 2006 May 01; 52(5):e133-7. PubMed ID: 16427702 [Abstract] [Full Text] [Related]
11. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, Rubin RH, Wingard JR, DePauw B, Schlamm HT, Troke P, Bennett JE, European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG), Pfizer Global Aspergillus Study Group. Clin Infect Dis; 2005 Nov 15; 41(10):1448-52. PubMed ID: 16231256 [Abstract] [Full Text] [Related]
13. [Experience with voriconazole in invasive aspergillosis]. Thiel E, Schwartz S. Mycoses; 2003 Nov 15; 46 Suppl 2():3-7. PubMed ID: 15055137 [Abstract] [Full Text] [Related]